Intrexon Corporation (Public - NYSE: XON) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.
Japan’s Marine Product Imports Exceed Domestic Production Japan
The following is an excerpt from an article published by nippon.com:
Japan’s fishing industry is not the force that it once was, and in 2022 the country imported marine products worth ¥2 tr...
Fish face vast decline if emissions are not reduced Worldwide
The following is an excerpt from an article published by Dialogue Earth:
Failing to keep warming to below 3C could mean a 30% decline in catchable fish in many countries, huge study suggests
Gl...
Korean Market Situation for Shrimp and Cuttlefish South Korea
As of June 2024, the volume of frozen whiteleg shrimp imported into the country recorded 235 tons, a 72% decrease compared to the same period last year, and this figure is a significant decrease from ...